Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Receivables (2019 - 2025)

Legend Biotech filings provide 7 years of Receivables readings, the most recent being $13.1 million for Q4 2025.

  • On a quarterly basis, Receivables rose 82.45% to $13.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $13.1 million, a 82.45% increase, with the full-year FY2025 number at $13.1 million, up 85.37% from a year prior.
  • Receivables hit $13.1 million in Q4 2025 for Legend Biotech, up from $1.2 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $100.8 million in Q4 2023 to a low of $1967.0 in Q1 2021.
  • Median Receivables over the past 5 years was $2.4 million (2021), compared with a mean of $16.0 million.
  • Biggest five-year swings in Receivables: soared 2599747.48% in 2022 and later tumbled 99.89% in 2023.
  • Legend Biotech's Receivables stood at $51.2 million in 2021, then tumbled by 97.97% to $1.0 million in 2022, then soared by 9613.97% to $100.8 million in 2023, then crashed by 92.88% to $7.2 million in 2024, then soared by 82.45% to $13.1 million in 2025.
  • The last three reported values for Receivables were $13.1 million (Q4 2025), $1.2 million (Q3 2025), and $27.6 million (Q2 2025) per Business Quant data.